KCM
IMMU

Kennedy Capital Management’s Immunomedics Inc IMMU Stock Holding History

Kennedy Capital Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-192,824
Closed -$4.02M – 766
2018
Q3 		$4.02M Buy
+192,824
New +$4.57M 0.07% 463

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Kennedy Capital Management's IMMU Position: Q4 2018 in Review

Kennedy Capital Management sold out of Immunomedics Inc (IMMU) in Q4 2018, closing a stake of 192,824 shares — an estimated $4.02M sold.

Kennedy Capital Management first reported a position in IMMU in Q3 2018 and held it in 1 quarter. The position peaked at $4.02M in Q3 2018. 205 funds tracked by Wall St. Rank hold IMMU as of Q4 2018.

  • Kennedy Capital Management reported no remaining Immunomedics Inc position as of Q4 2018 after selling out during the quarter.
  • Kennedy Capital Management sold 192,824 Immunomedics Inc shares in Q4 2018, an estimated $4.02M.
  • Kennedy Capital Management first reported a position in Immunomedics Inc in Q3 2018 and held it in 1 quarter.
  • Kennedy Capital Management's Immunomedics Inc position peaked at $4.02M in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2018.

Based on Kennedy Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.